The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species
Open accessAbstract
Replacing or editing disease-causing mutations holds great promise for treating many human diseases. Yet, delivering therapeutic genetic modifiers to specific cells in vivo has been challenging, particularly in large, anatomically distributed tissues such as skeletal muscle. Here, we establish an in vivo strategy to evolve and stringently select capsid variants of adeno-associated viruses (AAVs) that enable potent delivery to desired tissues. Using this method, we identify a class of RGD motif-containing capsids that transduces muscle with superior efficiency and selectivity after intravenous injection in mice and non-human primates. We demonstrate substantially enhanced potency and therapeutic efficacy of these engineered vectors compared to naturally occurring AAV capsids in two mouse models of genetic muscle disease. The top capsid variants from our selection approach show conserved potency for delivery across a variety of inbred mouse strains, and in cynomolgus macaques and human primary myotubes, with transduction dependent on target cell expressed integrin heterodimers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Pierschbacher, M. D., & Ruoslahti, E. (1984) · Nature · doi:10.1038/309030a0 · Cited by 3,658
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191 · cited 8×
“Finally, to investigate if integrin heterodimers and AAVR play redundant roles in MyoAAV 1A transduction, we overexpressed ɑ8b1, ɑVb1, ɑVb3, ɑVb6, or ɑVb8 in the HEK293FT AAVR KO (C) Different tissues of 8-week-old C57BL/6J mice systemically injected with 2E EGFP (right) illuminated by blue light.”
InfluentialAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 1×
“However, the majority of in vivo capsid directed evolution strategies select successful capsid variants based on presence in the tissue of interest of the vector genome DNA, rather than the transgene mRNA (Li and Samulski, 2020).”
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Pytela, R., Pierschbacher, M. D., & Ruoslahti, E. (1985) · Cell · doi:10.1016/0092-8674(85)90322-8 · Cited by 1,101
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046 · cited 9×
“…that this CRISPR-Cas9-mediated approach results in excision of exon 23 from the genome of mdx cells and expression of a truncated but still in-frame and functional version of dystrophin protein that provides therapeutic benefit in dystrophic muscle (Nelson et al., 2016; Tabebordbar et al., 2016).”
BackgroundMethodSelf-citationHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 2×
“modified vectors for augmented delivery to a number of tissues (Choudhury et al., 2016; Dalkara et al., 2013; Deverman et al., 2016; Körbelin et al., 2016; Li et al., 2016; Michelfelder et al., 2009; Nonnenmacher et al., 2020; Tse et al., 2017; Yang et al., 2009; Yang and Xiao, 2013).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
An essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Highly Efficient, Functional Engraftment of Skeletal Muscle Stem Cells in Dystrophic Muscles
Cerletti, M., Jurga, S., Witczak, C. A., Hirshman, M. F., Shadrach, J. L., Goodyear, L. J., & Wagers, A. J. (2008) · Cell · doi:10.1016/j.cell.2008.05.049 · Cited by 472
Self-citationThe Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Hordeaux, J., Wang, Q., Katz, N., Buza, E. L., Bell, P., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.018 · Cited by 426
Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Definition of an efficient synthetic poly(A) site.
Levitt, N., Briggs, D., Gil, A., & Proudfoot, N. J. (1989) · Genes & Development · doi:10.1101/gad.3.7.1019 · Cited by 290
Weinmann, J., Weis, S., Sippel, J., Tulalamba, W., Remes, A., El Andari, J., Herrmann, A.-K., Pham, Q. H., Borowski, C., Hille, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19230-w · Cited by 259
Intracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Structural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection
Yang, L., Jiang, J., Drouin, L. M., Agbandje-Mckenna, M., Chen, C., Qiao, C., Pu, D., Hu, X., Wang, D.-Z., Li, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813207106 · Cited by 210
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190
Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Childers, M. K., Joubert, R., Poulard, K., Moal, C., Grange, R. W., Doering, J. A., Lawlor, M. W., Rider, B. E., Jamet, T., Danièle, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007523 · Cited by 173
Self-citationBiology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates
Gao, G., Lu, Y., Calcedo, R., Grant, R. L., Bell, P., Wang, L., Figueredo, J., Lock, M., & Wilson, J. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.017 · Cited by 170
Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning
Nonnenmacher, M., Wang, W., Child, M. A., Ren, X.-Q., Huang, C., Ren, A. Z., Tocci, J., Chen, Q., Bittner, K., Tyson, K., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.006 · Cited by 168
Alexander, M. S., Casar, J. C., Motohashi, N., Vieira, N. M., Eisenberg, I., Marshall, J. L., Gasperini, M. J., Lek, A., Myers, J. A., Estrella, E. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73579 · Cited by 160
Self-citationAn Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor
Dudek, A. M., Pillay, S., Puschnik, A. S., Nagamine, C. M., Cheng, F., Qiu, J., Carette, J. E., & Vandenberghe, L. H. (2018) · Journal of Virology · doi:10.1128/jvi.02213-17 · Cited by 128
In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy
Choudhury, S., Fitzpatrick, Z., Harris, A. F., Maitland, S. A., Ferreira, J. S., Zhang, Y., Ma, S., Sharma, R. B., Gray‐Edwards, H. L., Johnson, J. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.84 · Cited by 125
Hakim, C. H., Wasala, N. B., Pan, X., Kodippili, K., Yue, Y., Zhang, K., Yao, G., Haffner, B., Duan, S. X., Ramos, J. N., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.006 · Cited by 118
Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs
Mack, D. L., Poulard, K., Goddard, M. A., Latournerie, V., Snyder, J. M., Grange, R. W., Elverman, M. R., Denard, J., Veron, P., Buscara, L., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.004 · Cited by 114
Self-citationKörbelin, J., Sieber, T., Michelfelder, S., Lunding, L. P., Spies, E., Hunger, A., Alawi, M., Rapti, K., Indenbirken, D., Müller, O. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.62 · Cited by 93
Murrey, D. A., Naughton, B. J., Duncan, F. J., Meadows, A. S., Bobo, T. A., Campbell, K., Bremer, W. G., Walker, C. M., Goodchild, L., Bolon, B. N., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.208 · Cited by 92
Cellular transduction mechanisms of adeno-associated viral vectors
Berry, G. E., & Asokan, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.001 · Cited by 92
Chan, S., Head, S. I., & Morley, J. W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00128.2007 · Cited by 88
Morales, L., Gambhir, Y., Bennett, J., & Stedman, H. H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.009 · Cited by 86
Michelfelder, S., Kohlschütter, J., Skorupa, A., Pfennings, S., Müller, O. J., Kleinschmidt, J. A., & Trepel, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005122 · Cited by 75
Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening
Börner, K., Kienle, E., Huang, L., Weinmann, J., Sacher, A., Bayer, P., Stüllein, C., Fakhiri, J., Zimmermann, L., Westhaus, A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.02.009 · Cited by 72
Long-term effects of systemic gene therapy in a canine model of myotubular myopathy
Elverman, M., Goddard, M. A., Mack, D., Snyder, J. M., Lawlor, M. W., Meng, H., Beggs, A. H., Buj‐Bello, A., Poulard, K., Marsh, A. P., et al. (2017) · Muscle & Nerve · doi:10.1002/mus.25658 · Cited by 65
Self-citationHuman skeletal muscle xenograft as a new preclinical model for muscle disorders
Zhang, T., King, O. D., Rahimov, F., Jones, T. I., Ward, C. W., Kerr, J. P., Liu, N., Emerson, C. P., Kunkel, L. M., Partridge, T. A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu028 · Cited by 61
In Situ Modification of Tissue Stem and Progenitor Cell Genomes
Goldstein, J. M., Tabebordbar, M., Zhu, K., Wang, L. D., Messemer, K. A., Peacker, B. L., Kakhki, S. A., Gonzalez-Celeiro, M., Shwartz, Y., Cheng, J. K. W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.105 · Cited by 54
Self-citationLi, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution
Yang, L., & Xiao, X. (2013) · Virology Journal · doi:10.1186/1743-422x-10-50 · Cited by 22
Challis, R. C., Kumar, S. R., Chan, K. Y., Challis, C., Jang, M. J., Rajendran, P. S., Tompkins, J. D., Shivkumar, K., Deverman, B. E., & Gradinaru, V. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/246405 · Cited by 17
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259
Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice
Chai, A. C., Cui, M., Chemello, F., Li, H., Chen, K., Tan, W., Atmanli, A., McAnally, J. R., Zhang, Y., Xu, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02176-5 · Cited by 184
Metadata
- Authors
- Tabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., Troiano, E. C., Moghadaszadeh, B., Peacker, B. L., Leacock, K. A., Horwitz, N., Beggs, A. H., Wagers, A. J., & Sabeti, P. C.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 184
- Issue
- 19
- Pages
- 4919-4938.e22
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3198514921
- Cited by
- 506
- References
- 49
- FWCI
- 34.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.